EPIRUBICIN, CISPLATIN AND INFUSIONAL 5-FLUOROURACIL (5-FU) (ECF) IN HEPATOBILIARY TUMORS
EPIRUBICIN, CISPLATIN AND INFUSIONAL 5-FLUOROURACIL (5-FU) (ECF) IN HEPATOBILIARY TUMORS
复制标题
DOI：
10.1016/0959-8049(95)00323-b
复制
发表时间：
1995-09-01
影响因子：
8.4
通讯作者：
CUNNINGHAM, D
中科院分区：
文献类型：
--
作者：
ELLIS, PA;NORMAN, A;CUNNINGHAM, D
肝胆肿瘤很少见，通常出现较晚，预后较差，目前尚无有效的全身治疗方法。本研究旨在评估表阿霉素、顺铂和持续输注 5-氟尿嘧啶 (5-FU) (ECF) 对这些肿瘤患者的活性和毒性。 1991年3月至1993年11月，25例晚期胆道肿瘤患者和7例肝癌患者在第1天静脉注射表阿霉素50 mg/m(2)和顺铂60 mg/m(2)，每21天一次，并连续24小时静脉注射5-FU 200 mg/m(2)/天。整个治疗过程中输液。 20 名可评估的胆道肿瘤患者中有 8 名 (40%) 有反应。中位缓解持续时间为 10 个月。 7 名肝癌患者中有 2 名（29%）有反应。该方案耐受性良好，血液学和非血液学毒性最小。这种新疗法对晚期肝胆肿瘤有效。
Hepatobiliary tumours are rare, often present late and have a poor prognosis, with no current effective systemic therapy available. This study aimed to evaluate the activity and toxicity of epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) in patients with these tumours. From March 1991 to November 1993, 25 patients with advanced biliary tumours and 7 with hepatoma were treated with epirubicin 50 mg/m(2) and cisplatin 60 mg/m(2) intravenously (i.v.) day 1, each given every 21 days and 5-FU 200 mg/m(2)/day given as a continuous 24 h i.v. infusion throughout the treatment course. 8 of the 20 (40%) evaluable patients with biliary tumours responded. Median duration of response was 10 months. 2 of the 7 (29%) patients with hepatoma responded. The regimen was well tolerated with minimal haematological and non-haematological toxicity. This novel regimen is active in advanced hepatobiliary tumours.